ClinicalTrials.gg
RecruitingNCT05641493Updated Apr 10, 2023

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

A Phase 1/2 interventional study of HLX208+HLX10 in Non Small Cell Lung Cancer, sponsored by Shanghai Henlius Biotech. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-04-10.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing serplulimab in Carcinoma, Non-Small-Cell Lung — 5 open to participants now, 7 under way, none of them phase 3. serplulimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
6th of 10
49 · median 50
Started
2023
with 5 others
Phase 1/2
Only one
of the 10
Registered
2nd of 10
by date
Lead sponsor
2 of 10
Shanghai Henlius Biotech

Among the 10 studies testing serplulimab in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by planned enrollment, is one of 6 that started in 2023, is the only one in phase 1/2, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 10 studies testing serplulimab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About serplulimab

serplulimab: first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing serplulimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

An open-label, multicenter phase Ib/II clinical study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HLX208 (BRAF V600E Inhibitor) combined with HLX10 (anti-PD-1 monoclonal antibody)in advanced NSCLC patients with BRAF V600 mutation.

Read the detailed description

This is an open-label, multicenter phase Ib/II clinical study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HLX208 (BRAF V600E Inhibitor) combined with HLX10 (anti-PD-1 monoclonal antibody)in advanced NSCLC patients with BRAF V600 mutation.

For the phase Ib study, HLX208 is administered orally at two dose levels of 600mg BID or 900 mg BID. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks.

For the phase II study, HLX208 is administered orally with the RP2D dose. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • HLX208
  • HLX10
  • BRAF V600E mutation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 and ≤75 years old of age (in phase Ib study) or ≥18 and ≤80 years old of ag (in phase II study) at the time of .
  2. Signed written informed consent.
  3. BRAF V600E mutant advanced solid tumors (in phase Ib study) or advanced NSCLC (in phase II study) patients with positive expression (TPS or TC≥1%).
  4. Previous failure of standard therapy, intolerance to standard therapy, lack of standard therapy, or currently unsuitable for standard therapy.
  5. Prior systemic anti-neoplastic therapy (chemotherapy, radiotherapy, targeted therapy, or traditional Chinese medicine with anti-neoplastic indications) must have been ≥ 2 weeks from the first dose in this study with treatment-related AE resolved to Grade ≤ 1 (except for alopecia)
  6. (ECOG) Performance Status of 0-1.
  7. Expected survival time ≥ 3 months.
  8. At least one measurable target lesion per v1.1 ( could not be considered as the only ).
  9. With normal major organ functions (no blood transfusions or treatment with colony-stimulating factor within 14 days prior to the first dose in this study).
  10. Be able to swallow and retain oral medication and must not have any gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bow
  11. Fertile subjects (male or female) must agree to take effective measures from the time of signing the ICF until 90 days after the last dose of HLX208 or 6 months after the last dose of HLX10. Female subjects of must complete a pregnancy test with a negative result within 7 days prior to the first dose.

Exclusion criteria

Exclusion Criteria:

  1. For subjects in phase II study: previous treatment with BRAF inhibitors or MEK inhibitors or previous treatment with T cell co-stimulation or immune checkpoint therapy.
  2. Known EGFR mutations or ALK rearrangements (except in subjects with EGFR mutations whose disease has progressed after previous EGFR inhibitor treatment).
  3. Received strong inhibitors or inducers treatment within 1 week prior to the first dose of product.
  4. Received major surgery within 28 days prior to the first dose of investigational product. A major surgery is defined as a surgery that takes at least 3 weeks of postoperative recovery before receiving treatment in this study.
  5. With uncontrolled pleural effusion, pericardial effusion, or ascites.
  6. With symptomatic brain or meningeal (unless the patient has been treated for >3 months, there is no evidence of progression on imaging within 4 weeks prior to the first dose, and the tumor-related clinical symptoms are stable).
  7. With active pulmonary tuberculosis. Patients with previous and current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity.
  8. With any serious infection requiring systemic anti-infective therapy within 14 days prior to the first dose of the investigational product.
  9. History of other malignant tumors (except for cured carcinoma in situ of the cervical or basal cell carcinoma of the skin) within two years prior to the first dose of investigational product.
  10. Being positive (+) for surface antigen (HBsAg) or positive (+) for hepatitis B core antibody (HBcAb), and with hepatitis B virus deoxyribonucleic acid (HBV-DNA) ≥ 2500 copies/mL or 500 IU/mL.
  11. Being positive (+) for .
  12. Being positive (+) (HIV) antibody.
  13. History of serious cardiovascular and cerebrovascular diseases.
  14. Systemic treatment with (> 10 mg/day prednisone or equivalent) or other agents within 14 days prior to the first dose of the investigational product or during the study. In the absence of active disease, subjects are allowed to use inhaled or topical steroids, or adrenal hormone replacement therapy at an effective dose equivalent to ≤10 mg/day prednisone.
  15. Known active or suspected autoimmune diseases. Subjects with autoimmune related hypothyroidism receiving thyroid hormone replacement therapy are allowed to participate in the study. Subjects with stable type 1 diabetes receiving insulin therapy are allowed to participate in the study.
  16. Known alcohol of or drug abuse.
  17. Pregnant or lactating women.
  18. Received within 28 days prior to the first dose of investigational product.
  19. Have other conditions not suitable for inclusion as judged by the investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    HLX208 combined HLX10

    For the phase Ib study, HLX208 is administered orally at two dose levels of 600mg BID or 900 mg BID. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks. For the phase II study, HLX208 is administered orally with the RP2D dose. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks.

    Combination Product: HLX208+HLX10

Interventions

06

What researchers measure

Primary outcomes

  1. MTD (for phase Ib study)

    The maximum tolerated dose of HLX208 combined with HLX10.

    Time frame: From first dose to the end of Cycle 1 (each cycle is 3 weeks).

  2. DLT (for phase Ib study)

    The proportion of patients experiencing dose limiting toxicity (DLT) events.

    Time frame: From first dose to the end of Cycle 1 (each cycle is 3 weeks).

  3. ORR (for phase II study)

    Objective response rate assessed by the investigator per RECIST 1.1.

    Time frame: up to approximately up to 24 months

Secondary outcomes

  1. PFS

    Progression-Free-Survival

    Time frame: approximately up to 36 months

  2. DCR

    Disease-Control-Rate

    Time frame: approximately up to 24 months

  3. DOR

    Duration of Overall Response

    Time frame: approximately up to 24 months

  4. TTR

    Time to Tumor Response

    Time frame: approximately up to 24 months

  5. 12-month OS rate

    12-month OS rate

    Time frame: 12 months

  6. 6-month OS rate

    6-month OS rate

    Time frame: 6 months

  7. OS

    Overall-Survival

    Time frame: approximately up to 48 months

  8. 12-month PFS rate

    12-month PFS rate

    Time frame: 12 months

  9. 6-month PFS rate

    6-month PFS rate

    Time frame: 6 months

  10. SAE

    The proportion of patients experiencing SAE.

    Time frame: approximately up to 48 months

  11. AUC0-T

    Area under the concentration-time curve from time 0 to the last concentration measurable time point.

    Time frame: From First administration of HLX 208 to 12 weeks.

  12. AUC0-∞

    Area under the concentration-time curve from time 0 to infinity.

    Time frame: From First administration of HLX 208 to 12 weeks.

  13. Cmax

    Peak Plasma Concentration.

    Time frame: From First administration of HLX 208 to 12 weeks.

  14. Tmax

    Time to first occurrence of Cmax

    Time frame: From First administration of HLX 208 to 12 weeks.

  15. t1/2

    Elimination half-life

    Time frame: From First administration of HLX 208 to 12 weeks.

  16. AUCss

    Area under the steady-state concentration-time curve

    Time frame: From First administration of HLX 208 to 12 weeks.

Other outcomes

  1. Association of biomarkers with efficacy

    Association of efficacy with biomarkers including PD-L1 expression, BRAF V600E mutation abundance, MSI status and TMB status.

    Time frame: approximately up to 48 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Mar 2025, 24 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 24 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2022
First posted
Dec 7, 2022
StartActual
Feb 28, 2023
Primary completionEst.
Mar 4, 2025
CompletionEst.
Feb 27, 2026
Last update
Apr 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05641493
Responsible party
Sponsor
First posted
Dec 7, 2022
Start date
Feb 28, 2023
Primary completion
Mar 4, 2025 (estimated)
Completion
Feb 27, 2026 (estimated)
Last update
Apr 10, 2023

Study contacts

Shun Lu, Dr.
Contact
shunlu@sjtu.edu.cn
021-22200000
Shun Lu, Dr.
principal investigator · Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BRAF V600E Inhibitor HLX208 · Serplulimab

Start the discussion